The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial
Abstract
OBJECTIVE: Hypoglycemia is a leading risk of glucose-lowering therapy. Treatment with insulin glargine compared with standard care early in the course of dysglycemia in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial provides information on the frequency and predictors of hypoglycemia in this setting. RESEARCH DESIGN AND METHODS: A total of 12,537 people with high cardiovascular risk and dysglycemia treated with one or no oral glucose-lowering agents were randomized to add glargine titrated to a fasting glucose level of ≤5.3 mmol/L (≤95 mg/dL) or to use standard therapies. Independent associations of both nonsevere hypoglycemia (symptomatic and confirmed with a glucose level of ≤3 mmol/L [≤54 mg/dL]) and severe hypoglycemia with characteristics at baseline, treatment allocation, and average HbA1c were assessed by Cox proportional hazards models. RESULTS: During a median follow-up period of 6.2 years, 28% of participants reported nonsevere hypoglycemia, and 3.8% reported severe hypoglycemia. Prior use of a sulfonylurea and allocation to glargine independently predicted a higher risk for both categories of participants. Nonsevere events were independently associated with younger age, lower BMI, the presence of diabetes, and higher baseline HbA1c level. Severe events were associated with older age, hypertension, higher serum creatinine level, and lower cognitive function, but not baseline glycemic status. Progressively higher on-treatment HbA1c level was associated with a lower risk of nonsevere events in both treatment groups; a lower risk of severe events in the glargine group, and a higher risk of severe events with standard care. CONCLUSIONS: Hypoglycemia was relatively uncommon in the ORIGIN trial, but was more frequent with sulfonylurea use at baseline and allocation to glargine. Nonsevere and severe events were associated with different clinical characteristics, awareness of which may guide individualized therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar results were confirmed in other trials.140,187,188”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [188]
Citations
Cites
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
Hypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381
Hypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341 · cited 1×
“Thus, consistent with other reports (11,12), younger age, lower BMI, depression, a history of diabetes, a higher baseline HbA1c level, and a lower HbA1c level achieved during therapy were independently associated with nonsevere hypoglycemia.”
ResultDoes hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht332 · Cited by 247
Self-citation
Cited by
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
“The chronic health conditions most often implicated in increasing hypoglycemia risk are kidney disease,[5, 66, 74, 76, 78, 85] cognitive impairment, [81, 87–89] cardiovascular disease,[66, 77] depression,[66, 79] and heart failure.”
Lee, A. K., Warren, B., Lee, C. J., McEvoy, J. W., Matsushita, K., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2018) · Diabetes Care · doi:10.2337/dc17-1669 · Cited by 226
Minimizing Hypoglycemia in Diabetes
International Hypoglycaemia Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0279 · Cited by 209
“Findings of differences in clinical associations with symptomatic and severe hypoglycemia (33) suggest that hypoglycemic events that do or do not require”
BackgroundPathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
“Rates of severe hypoglycemia observed in this and other communitybased populations are higher than the rates reported in clinical trials among subjects with type 2 diabetes treated by protocol to very low A1C levels (11,12,18,25,28,38).”
BackgroundResultLee, A. K., Lee, C. J., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2017) · Diabetes Care · doi:10.2337/dc17-0819 · Cited by 119
“Prospective cohort studies (15,26,30,31) looking at depression and”
BackgroundResultDiabetes, Dementia and Hypoglycemia
Meneilly, G. S., & Tessier, D. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.006 · Cited by 109
Conlin, P. R., Colburn, J. A., Aron, D. C., Pries, R. M., Tschanz, M. P., & POGACH, L. M. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1362 · Cited by 101
Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
McIntosh, E. C., Nation, D. A., & Initiative, A. D. N. (2019) · Diabetes Care · doi:10.2337/dc18-1399 · Cited by 87
Abdelhafiz, A. H., McNicholas, E., & Sinclair, A. J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.027 · Cited by 76
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus
Connelly, K. A., Yan, A. T.-K., Leiter, L. A., Bhatt, D. L., & Verma, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015946 · Cited by 54
Use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes
Weiner, J. Z., Gopalan, A., Mishra, P., Lipska, K. J., Huang, E. S., Laiteerapong, N., Karter, A. J., & Grant, R. W. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.3759 · Cited by 47
The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology
Yang, S., Park, K., & Zhou, Y.-J. (2015) · Angiology · doi:10.1177/0003319715623400 · Cited by 55
“And the misperception has been corrected by the findings of a series of epidemiological or cohort investigations, which revealed that severe hypoglycemia events are not rare in insulintreated as well as sulfonylurea-treated type 2 DM.(6-10)”
BackgroundBasal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 44
“The analysis of predictors of hypoglycemia accompanying the use of glargine 100 units/mL described above suggests that individuals who have low BMI and low basal insulin requirements might be most likely to have more stable glycemic control with a longer-acting insulin (12).”
BackgroundZhang, L., Yang, L., & Zhou, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1044059 · Cited by 46
Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes
McCoy, R. G., Herrin, J., Lipska, K. J., & Shah, N. D. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.007 · Cited by 40
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial
Cukierman‐Yaffe, T., Bosch, J., Jung, H. J., Punthakee, Z., & Gerstein, H. C. (2018) · Diabetes Care · doi:10.2337/dc18-0690 · Cited by 40
Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 44
Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes
Malkani, S., & Kotwal, A. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7425925 · Cited by 32
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 32
Rooney, M. R., Tang, O., Echouffo-Tcheugui, J. B., Lutsey, P. L., Grams, M. E., Windham, B. G., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-3045 · Cited by 25
Owens, D. R., Landgraf, W., Frier, B. M., Zhang, M., Home, P., Meneghini, L., & Bolli, G. B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13607 · Cited by 23
Hypoglycemia and cognitive function in diabetic patients
Ebadi, S. A., Darvish, P., Fard, A. J., Lima, B. S., & Ahangar, O. G. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.05.011 · Cited by 22
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Thiès, F., Aucott, L. S., & Macleod, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815 · Cited by 22
Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes
Mahoney, G. K., Henk, H. J., & McCoy, R. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.02.028 · Cited by 26
Farngren, J., & Åhrén, B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.016 · Cited by 21
Association between mild and severe hypoglycemia in people with type 2 diabetes initiating insulin
Festa, A., Heller, S. R., Seaquist, E. R., Duan, R., Hadjiyianni, I., & Fu, H. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.12.014 · Cited by 20
Aberer, F., Pferschy, P. N., Tripolt, N. J., Sourij, C., Obermayer, A. M., Prüller, F., Novak, E., Reitbauer, P., Kojzar, H., Prietl, B., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13889 · Cited by 19
Jeon, J. Y., Kim, S. R., Kim, H. J., Kim, D. J., Lee, K. W., Lee, J.-D., & Han, S. J. (2016) · Medicine · doi:10.1097/md.0000000000005365 · Cited by 22
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
Tschanz, M. P., Watts, S. A., Colburn, J. A., Conlin, P. R., & POGACH, L. M. (2017) · Europe PMC (PubMed Central) · Cited by 20
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Cahn, A., Raz, I., Mosenzon, O., Leibowitz, G., Yanuv, I., Rozenberg, A., Iqbal, N., Hirshberg, B., Sjöstrand, M., Stahre, C., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2763 · Cited by 16
“Declining renal function and increasing levels of urinary microalbumin have been shown to be predictors of hypoglycemia (28,29) and probably represent both an independent effect of decreased insulin clearance associated with reduced GFR and the vulnerability of the population with impaired renal function”
BackgroundGu, W., Ren, Y., Ji, L., Hong, T., Mu, Y., Guo, L., Li, Q., Tian, Q., & Yang, X. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.024 · Cited by 16
Lingvay, I., Harris, S. B., Jaeckel, E., Chandarana, K., Ranthe, M. F., & Jódar, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13043 · Cited by 15
“An explanation for this could be that patients with lower BMI tend to be more insulin sensitive and, therefore, may be more vulnerable to insulin-induced hypoglycaemia.(15) The interpretation of our analysis is limited by its post hoc nature and by the fact that patients with a very high HbA1c level (>10%) or BMI (>40…”
BackgroundAu, N. H., Ratzki-Leewing, A., Zou, G., Ryan, B. L., Webster-Bogaert, S., Reichert, S. M., Brown, J. B., & Harris, S. B. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.09.004 · Cited by 14
Porcellati, F., Lin, J., Lucidi, P., Bolli, G. B., & Fanelli, C. G. (2017) · Medicine · doi:10.1097/md.0000000000006022 · Cited by 17
Hu, X., Xu, W., Lin, S., Zhang, C., Ling, C., & Chen, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7292108 · Cited by 14
“Riddle included patients with high cardiovascular disease risk and abnormal blood sugar and reached similar conclusions [36].”
ResultHypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies
Pistrosch, F., & Hanefeld, M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0678-2 · Cited by 14
Owens, D. R., Bolli, G. B., Charbonnel, B. H., Haak, T., Landgraf, W., Porcellati, F., Traylor, L., & Kautzky‐Willer, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12966 · Cited by 11
Wolffenbuttel, B. H. R., Gaal, L. V., Durán-Garcia, S., & Han, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12669 · Cited by 10
Long-term studies of treatments for type 2 diabetes
Caballero, A. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1265417 · Cited by 12
“Glargine was associated with an increased risk of hypoglycemia (Table 1) [63].”
BackgroundNguyen, J. V., Roseberry, S., Rivas, J. A., & Cauthon, K. A. B. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.112 · Cited by 10
Li, T., Li, W., Wu, Y., Wu, Q., Zhao, G., Cai, Z., Pu, F., & Li, B. (2021) · Medicine · doi:10.1097/md.0000000000023578 · Cited by 10
Chen, L., Tang, Y., Huang, J., Liu, S., & Xing, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.975468 · Cited by 13
Piątkiewicz, P., Buraczewska-Leszczyńska, B., Kuczerowski, R., Bernat-Karpińska, M., Rabijewski, M., & Kowrach, M. (2016) · Kardiologia Polska · doi:10.5603/kp.a2016.0043 · Cited by 10
“Such factors as old age, arterial hypertension, increased creatinine level, and lower cognitive function make persons with diabetes type 2 susceptible to severe hypoglycaemia [15].”
BackgroundMarine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Aucott, L. S., & Thiès, F. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815.pub2 · Cited by 12
Huang, B., Jiang, Q., Wu, T., Shen, Q., Wang, W., Wang, S., Huang, Y., Wang, S., Huang, P., Lin, M., et al. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00959-x · Cited by 8
“Prior research found that lower HbA1c was an independent predictor of AH [28, 30, 31]; this was also highly salient in the current cohort.”
BackgroundResultLEVIN, P. A., Fan, T., Song, X., Nero, D., Davis, B., & Chu, B. C. (2017) · Endocrine Practice · doi:10.4158/ep171769.or · Cited by 7
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Aucott, L. S., & Thiès, F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815.pub3 · Cited by 8
Mönnig, E., Spaepen, E., Osumili, B., Mitchell, B. D., Snoek, F. J., Peyrot, M. F., Kern, W., & Holstein, A. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1310-7963 · Cited by 6
He, Y., Kunutsor, S. K., Kingsnorth, A. P., Gillies, C., Choudhary, P., Khunti, K., & Zaccardi, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15677 · Cited by 5
Practical considerations for managing patients with diabetes and dementia
Mair, M. L., Athavale, R., & Abdelhafiz, A. H. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1395692 · Cited by 4
Home, P. D., Calvi-Gries, F., Blonde, L., Pilorget, V., Berlingieri, J., & Freemantle, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13179 · Cited by 4
A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus
Brož, J., & Urbanová, J. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.050 · Cited by 5
Wang, Y., Jiang, Y., Li, L., Chen, H., Wang, J., Zhang, M., Bai, X., & Wu, S. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501759 · Cited by 4
Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes
Moutairou, A., Roussel, R., Charbonnel, B. H., Lèye, A., Detournay, B., Mohammedi, K., & Potier, L. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.009 · Cited by 3
Chaves, W. G., Martínez, L., Díaz, D., Hernández, D., & Sanabria, M. C. (2019) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.6.4.545 · Cited by 4
Timple, V. S., SOLIMAN, E. D. P., Frulla, G., Kawar, L. N., & Nguyen, A. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000082 · Cited by 1
LACY, M. E., Whitmer, R. A., Lee, S. J., Rushakoff, R. J., & Pletcher, M. J. (2021) · Clinical Diabetes · doi:10.2337/cd20-0057 · Cited by 1
More and more elderly diabetics: toward evidence-based deprescribing?
Micheli, A. D. (2018) · The Journal of AMD · doi:10.36171/jamd18.21.1.02 · Cited by 1
Pathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C. X., Lafata, J. E., Thomas, A., Lawrence, J. M., Karter, A. J., Steiner, J. F., Segal, J. B., et al. (2017) · Diabetes Care · doi:10.2337/dci16-0037
Kattan, W. (2017) · STARS (University of Central Florida)
Risk Indicators of Non-severe Hypoglycemia in Type 2 Diabetes: An Analysis of Real World Data
Au, N. H. (2018) · Scholarship@Western (Western University)
Risk Management in Internal Medicine
Fukuzawa, Y., Yoshitomi, A., Maki, N., Tokunaga, A., & Nakamura, K. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.944
Seferovic, P. M., & Jhund, P. S. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz219
Les hypoglycémies et leurs conséquences dans l’essai DCCT
Moutairou, A. (2019) · theses.fr (ABES) · doi:10.70675/2381bb1ez244ez4e52z8a7dz46479a89bf4a
Future perspectives for diabetic retinopathy management
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00006-8
He, G., & Xing, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-2972208/v1
Merzlova, P. Y., Bulgakova, S. V., Kurmaev, D. P., & Treneva, E. V. (2024) · Science and Innovations in Medicine · doi:10.35693/sim626840
Huang, B., Jiang, Q., Wu, T., Shen, Q., Wang, W., Wang, S., Huang, Y., Wang, S., Huang, P., Lin, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21638856
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-28
- Volume
- 38
- Issue
- 1
- Pages
- 22-28
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2280616855
- Cited by
- 75
- References
- 23
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 10 · 2018: 8 · 2017: 17 · 2016: 9 · 2015: 6
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypoglycemia, insulin glargine, sulfonylureas, glucose-lowering therapy, ORIGIN trial, severe hypoglycemia, HbA1c, high cardiovascular risk, dysglycemia, type 2 diabetes, oral glucose-lowering agents
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Risk Factors, Sulfonylurea Compounds, Body Mass Index, Proportional Hazards Models, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.